Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A powerful antiarrhythmic drug that contains 35% iodine, so it may cause thyroid dysfunction in treated patients.
Administered orally and intravenously.
It is used occasionally in acute arrhythmias and chronically in preventive or maintenance treatments.
It is excreted in breast milk in significant amounts. Maternal plasma levels of between 4% and 60% have been measured in infants whose mothers were taking it (Plomp 1992, Strunge 1988, McKenna 1983), but no clinical problems have been observed in these infants (Hall 2003, Plomp 1992, Strunge 1988, McKenna 1983), except for a newborn who showed signs of hypothyroidism after his mother had taken amiodarone during pregnancy (Plomp 1992).
Its very long half-life, which can reach 100 days, should be taken into account.
Chronic use during breastfeeding is not recommended (Hotham 2015, Tan 2001), but if necessary due to poor response to other alternatives, cardiac and thyroid function checks in the infant are mandatory on a periodic basis (Basaria 2005, Bartalena 2001, Moretti 2000).
Isolated use to reverse acute arrhythmia does not significantly raise the levels of amiodarone in breast milk and neither in the plasma of infants, so stopping breastfeeding would not be necessary (Khurana 2014).
Experts (Hale 2017, p55) consider that if it has been taken during a maximum of 3 to 7 days, an interruption to breasfeeding of 24 to 48 hours is sufficient.